Sentence examples for most appropriate mutation from inspiring English sources

An important reason for caution here is the current debate about the most appropriate mutation rate for NRY coalescence estimates.

Germline BRCA mutations are associated with worse prostate cancer (PCa) outcomes; however, the most appropriate management for mutation carriers has not yet been investigated.

However, the observation of substantial copy number variation in C. elegans [ 53] suggests that it is probably most appropriate to apply a mutation rate calculation that includes indels, as we have done.

Further investigation will be needed to clarify the most appropriate detection sensitivity of RAS mutation as a companion diagnostics prior to anti-EGFR therapies.

Given mutation rate variation, the most appropriate metric is polymorphism normalized by divergence.

Mitochondrial DNA is the most appropriate marker in this instance as the mutation rate is rapid enough to provide variability over the time scales in question, and recombination is very unusual, enabling straightforward interpretation of the patterns observed [ 21].

Their works also indicated the importance of molecular techniques as the most appropriate tools for detecting and identifying specific mutations in carriers of affected families.

BM-NSCLC have been shown to respond to oral EGFR TKIs and these data highlight the potential value of detecting mutations for choosing the most appropriate targeted treatment and for surveillance strategies.

This study emphasizes the molecular heterogeneity of AIP and the importance of molecular techniques as the most appropriate tools for detecting and identifying specific mutations in carriers of affected families to avoid the contact with precipitating agents.

Therefore, unlike EGFR mutation status for erlotinib, the most appropriate biomarker for the selection of patients with NSCLC for cetuximab treatment appears to be the expression level of EGFR.

This finding, together with the likely limited intratumor heterogeneity of BRAF mutations, suggests that the metastatic stage of BRAF-mutated melanomas represents the most appropriate therapeutic setting for BRAF inhibitors.